- Email: [email protected]
4835142 Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity
New Patents results in a composition with excellent controlled released characteristics.
4834966 PHARMACEUTICAL COMPOSITION WITH ANALGESIC ACTIVITY Annibale Gazzaniga, Valter Gianesello, Federico Stroppolo, Luigi Vigano, Rescaldina, Italy assigned to Zambon S p A A pharmaceutical composition consisting of: Ibuprofen: 33-46% w/w L-arginine: 34-51% w/w Sodium bicarbonate: 9-29% w/w is useful for preparing soluble granulate pharmaceutical preparations.
4834983 PHARMACEUTICAL COMPOSITIONS Robert C Hider, Georg Kontoghiorghes, Michael I Stockham, Essex, United Kingdom assigned to National Research Development Corporation Pharmaceutical compositions containing an iron complex of 3-hydroxy-4-pyrone or of a 3hydroxy-4-pyrone in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by an aliphatic hydrocarbon group of 1 to 6 carbon atoms, are of value for the treatment of iron deficiency anaemia.
4834985 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION Gordo Elger, Stewart Leslie, Sandra T A Malkowska, Ronald B Miller, Philip J Neale, Huntingdon, United Kingdom assigned to Euroceltique S A A solid, controlled release, pharmaceutical composition comprising an active ingredient incorporated in a matrix comprising a first substance selected from a water soluble polydextrose and a water soluble cyclodextrin and a second substance selected from a C12-C36 fatty alcohol and a polyalkylene glycol. Preferably the first substance is a cyclodextrin, especially a
xi
beta-cyclodextrin, while the second substance is a C14-C22 fatty alcohol, especially stearyl alcohol, cetyl alcohol, cetostearyl alcohol or myristyl alcohol. The matrix may also contain a cellulose ether, especially a hydroxyalkylcellulose or a carboxyalkylcellulose.
4835142 POWDERY PHARMACEUTICAL COMPOSITION SUITABLE FOR APPLICATION TO MUCOSA OF ORAL OR NASAL CAVITY Yoshik Suzuki, Hiroshi Ikura, Hino, Japan assigned to Teijin Limited A powdery pharmaceutical composition for application to the mucosa of the oral or nasal cavity including: (a) a base selected from the group consisting of lower alkyl ethers of cellulose; (b) a pharmaceutically effective amount of a drug selected from the group consisting of steroid or glycyrrhizic acid type antiinflammatory agents; and (c) a stabilizer for the drug composed of at least one low irritant solid organic acid selected from the group consisting of saturated higher aliphatic monocarboxylic acids having 12 or more carbon atoms, aliphatic polycarboxylic acid, hydroxy aliphatic polycarboxylic acids, aromatic carboxylic acids, unsaturated lower aliphatic monocarboxylic acids having six or less carbon atoms, and cellulose derivatives having carboxyl group. This powdery pharmaceutical composition has extremely excellent stability in the steroid or glycyrrhizic acid type anti-inflammatory agent contained therein, low irritation of the mucosa of the oral or nasal cavity, and sustained release of the drug over an extended period of time.
4835145 16,17 ACETALS OF PREGNANE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Pete MacDonald, Milan, Italy assigned to Sicor Societa' Italiana Corticosteroidi S p A A compound exhibiting anti-inflammatory properties having the formula See Patent for Chemical Structure in which X is H, Hal or CH3COO-; R1 is CH3(CH2)2CH-; and R2 and R3 are separately H or Hal; and a pharmaceutical composition containing the same.
4834966 PHARMACEUTICAL COMPOSITION WITH ANALGESIC ACTIVITY Annibale Gazzaniga, Valter Gianesello, Federico Stroppolo, Luigi Vigano, Rescaldina, Italy assigned to Zambon S p A A pharmaceutical composition consisting of: Ibuprofen: 33-46% w/w L-arginine: 34-51% w/w Sodium bicarbonate: 9-29% w/w is useful for preparing soluble granulate pharmaceutical preparations.
4834983 PHARMACEUTICAL COMPOSITIONS Robert C Hider, Georg Kontoghiorghes, Michael I Stockham, Essex, United Kingdom assigned to National Research Development Corporation Pharmaceutical compositions containing an iron complex of 3-hydroxy-4-pyrone or of a 3hydroxy-4-pyrone in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by an aliphatic hydrocarbon group of 1 to 6 carbon atoms, are of value for the treatment of iron deficiency anaemia.
4834985 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION Gordo Elger, Stewart Leslie, Sandra T A Malkowska, Ronald B Miller, Philip J Neale, Huntingdon, United Kingdom assigned to Euroceltique S A A solid, controlled release, pharmaceutical composition comprising an active ingredient incorporated in a matrix comprising a first substance selected from a water soluble polydextrose and a water soluble cyclodextrin and a second substance selected from a C12-C36 fatty alcohol and a polyalkylene glycol. Preferably the first substance is a cyclodextrin, especially a
xi
beta-cyclodextrin, while the second substance is a C14-C22 fatty alcohol, especially stearyl alcohol, cetyl alcohol, cetostearyl alcohol or myristyl alcohol. The matrix may also contain a cellulose ether, especially a hydroxyalkylcellulose or a carboxyalkylcellulose.
4835142 POWDERY PHARMACEUTICAL COMPOSITION SUITABLE FOR APPLICATION TO MUCOSA OF ORAL OR NASAL CAVITY Yoshik Suzuki, Hiroshi Ikura, Hino, Japan assigned to Teijin Limited A powdery pharmaceutical composition for application to the mucosa of the oral or nasal cavity including: (a) a base selected from the group consisting of lower alkyl ethers of cellulose; (b) a pharmaceutically effective amount of a drug selected from the group consisting of steroid or glycyrrhizic acid type antiinflammatory agents; and (c) a stabilizer for the drug composed of at least one low irritant solid organic acid selected from the group consisting of saturated higher aliphatic monocarboxylic acids having 12 or more carbon atoms, aliphatic polycarboxylic acid, hydroxy aliphatic polycarboxylic acids, aromatic carboxylic acids, unsaturated lower aliphatic monocarboxylic acids having six or less carbon atoms, and cellulose derivatives having carboxyl group. This powdery pharmaceutical composition has extremely excellent stability in the steroid or glycyrrhizic acid type anti-inflammatory agent contained therein, low irritation of the mucosa of the oral or nasal cavity, and sustained release of the drug over an extended period of time.
4835145 16,17 ACETALS OF PREGNANE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Pete MacDonald, Milan, Italy assigned to Sicor Societa' Italiana Corticosteroidi S p A A compound exhibiting anti-inflammatory properties having the formula See Patent for Chemical Structure in which X is H, Hal or CH3COO-; R1 is CH3(CH2)2CH-; and R2 and R3 are separately H or Hal; and a pharmaceutical composition containing the same.